AU2011207104C1 - Methods and compositions for improved nerve conduction velocity - Google Patents
Methods and compositions for improved nerve conduction velocity Download PDFInfo
- Publication number
- AU2011207104C1 AU2011207104C1 AU2011207104A AU2011207104A AU2011207104C1 AU 2011207104 C1 AU2011207104 C1 AU 2011207104C1 AU 2011207104 A AU2011207104 A AU 2011207104A AU 2011207104 A AU2011207104 A AU 2011207104A AU 2011207104 C1 AU2011207104 C1 AU 2011207104C1
- Authority
- AU
- Australia
- Prior art keywords
- hydrogen
- compound
- alkyl
- formula
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29637510P | 2010-01-19 | 2010-01-19 | |
| US61/296,375 | 2010-01-19 | ||
| PCT/AU2011/000051 WO2011088504A1 (en) | 2010-01-19 | 2011-01-19 | Methods and compositions for improved nerve conduction velocity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2011207104A1 AU2011207104A1 (en) | 2012-07-26 |
| AU2011207104B2 AU2011207104B2 (en) | 2015-07-02 |
| AU2011207104C1 true AU2011207104C1 (en) | 2015-10-08 |
Family
ID=44306296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011207104A Ceased AU2011207104C1 (en) | 2010-01-19 | 2011-01-19 | Methods and compositions for improved nerve conduction velocity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9095587B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2525795B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6232184B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102821765A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011207104C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2787173C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2560327T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ601383A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011088504A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201205375B (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ605444A (en) * | 2010-07-21 | 2015-06-26 | Spinifex Pharm Pty Ltd | Salt and solvates of a tetrahydroisoquinoline derivative |
| US10391331B2 (en) * | 2011-03-29 | 2019-08-27 | Biolyst, Llc. | Systems and methods for use in treating sensory impairment |
| JP6232384B2 (ja) | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| JP6258867B2 (ja) | 2012-01-25 | 2018-01-10 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| EP2807171B1 (en) * | 2012-01-25 | 2020-08-12 | Novartis AG | Heterocyclic compounds and methods for their use |
| NZ630908A (en) * | 2013-07-08 | 2017-08-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
| CN107001337B (zh) | 2015-01-13 | 2021-05-04 | 诺华股份有限公司 | 作为血管紧张素ii型拮抗剂的吡咯烷衍生物 |
| ES2898635T3 (es) | 2015-03-12 | 2022-03-08 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
| KR102132761B1 (ko) * | 2017-06-09 | 2020-07-17 | 산동 단홍 파머수티컬 컴퍼니., 리미티드. | At2r 수용체 길항제로서의 카르복시산 유도체 |
| CN112585120B (zh) * | 2018-11-02 | 2022-11-11 | 山东丹红制药有限公司 | 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020816A1 (en) * | 1992-04-13 | 1993-10-28 | Zeneca Limited | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| WO2006066361A1 (en) * | 2004-12-24 | 2006-06-29 | The University Of Queensland | Method of treatment or prophylaxis |
| WO2007106938A1 (en) * | 2006-03-20 | 2007-09-27 | The University Of Queensland | Method of treatment or prophylaxis inflammatory pain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091390A (en) * | 1990-09-20 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| GB2337701A (en) * | 1998-05-26 | 1999-12-01 | United Medical And Dental Schools Of Guys St Thomas Hospitals | Treatment of ischemia with an angiotensin II antagonist |
| US7828840B2 (en) | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
-
2011
- 2011-01-19 ES ES11734246.9T patent/ES2560327T3/es active Active
- 2011-01-19 AU AU2011207104A patent/AU2011207104C1/en not_active Ceased
- 2011-01-19 CN CN2011800145791A patent/CN102821765A/zh active Pending
- 2011-01-19 CA CA2787173A patent/CA2787173C/en not_active Expired - Fee Related
- 2011-01-19 NZ NZ60138311A patent/NZ601383A/en not_active IP Right Cessation
- 2011-01-19 JP JP2012549209A patent/JP6232184B2/ja not_active Expired - Fee Related
- 2011-01-19 US US13/522,228 patent/US9095587B2/en not_active Expired - Fee Related
- 2011-01-19 EP EP11734246.9A patent/EP2525795B1/en active Active
- 2011-01-19 WO PCT/AU2011/000051 patent/WO2011088504A1/en not_active Ceased
- 2011-01-19 CN CN201711036658.8A patent/CN107744519A/zh active Pending
-
2012
- 2012-07-18 ZA ZA2012/05375A patent/ZA201205375B/en unknown
-
2016
- 2016-04-01 JP JP2016073914A patent/JP2016155846A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020816A1 (en) * | 1992-04-13 | 1993-10-28 | Zeneca Limited | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| WO2006066361A1 (en) * | 2004-12-24 | 2006-06-29 | The University Of Queensland | Method of treatment or prophylaxis |
| WO2007106938A1 (en) * | 2006-03-20 | 2007-09-27 | The University Of Queensland | Method of treatment or prophylaxis inflammatory pain |
Non-Patent Citations (3)
| Title |
|---|
| COPPEY, L.J., ET AL, "ACE inhibitor or angiotension II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats". Diabetes, 2006, vol. 55, no. 2, pages 341-348 * |
| KASSELMAN, L.J. AND RUTKOVE, S.B., "Local administration of angiotensin-2 leads to decreased sensory nerve conduction velocity in the rat". Society for Neuroscience Abstract Viewer and Itinerary Planner, 2008, abstract 351.18/Y28 * |
| MAXFIELD, E.K., ET AL, Diabetologia, 1993, vol. 36, no. 12, pages 1230-1237 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2525795B1 (en) | 2015-10-21 |
| JP2013517300A (ja) | 2013-05-16 |
| WO2011088504A1 (en) | 2011-07-28 |
| JP2016155846A (ja) | 2016-09-01 |
| CA2787173A1 (en) | 2011-07-28 |
| EP2525795A4 (en) | 2013-07-24 |
| ZA201205375B (en) | 2013-09-25 |
| CA2787173C (en) | 2018-05-01 |
| CN102821765A (zh) | 2012-12-12 |
| HK1176554A1 (en) | 2013-08-02 |
| AU2011207104A1 (en) | 2012-07-26 |
| JP6232184B2 (ja) | 2017-11-15 |
| CN107744519A (zh) | 2018-03-02 |
| ES2560327T3 (es) | 2016-02-18 |
| EP2525795A1 (en) | 2012-11-28 |
| NZ601383A (en) | 2014-07-25 |
| US9095587B2 (en) | 2015-08-04 |
| US20130131103A1 (en) | 2013-05-23 |
| AU2011207104B2 (en) | 2015-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011207104B2 (en) | Methods and compositions for improved nerve conduction velocity | |
| EP4114466B1 (en) | Treatment of pain and vasoconstriction | |
| JP2008308488A (ja) | 非麦角系の選択的d2受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤 | |
| JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および/または神経精神医学的障害を改善するための4−アミノピリジンの使用 | |
| JP2021098745A (ja) | プラダー・ウィリー症候群を治療する方法 | |
| US6218411B1 (en) | Therapeutics for diabetic complications | |
| KR20060127843A (ko) | 가령 황반 변성 치료제 | |
| KR20040029358A (ko) | 간질성 방광염 치료용 의약 조성물 | |
| US20060167026A1 (en) | Antipsychotic molecular-targeting epithelial growth factor receptor | |
| US20210361624A1 (en) | Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals | |
| CN101636391B (zh) | 神经病理性疼痛的预防剂和/或治疗剂 | |
| LANGHAM et al. | The action of protriptyline on adrenergic mechanisms in rabbit, primate and human eyes | |
| US20200360303A1 (en) | Method for treating hyperhidrosis | |
| HK1176554B (en) | Methods and compositions for improved nerve conduction velocity | |
| KR20200135814A (ko) | 신규 중추-작용성 그렐린 효능제 및 그의 의학적 용도 | |
| US6214849B1 (en) | Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans | |
| SK7832000A3 (en) | New use of local anaesthetics against vascular headaches | |
| Corletto et al. | Pharmacological treatment of pain | |
| WO2016014229A1 (en) | Oxytocin improves treatment of obstructive sleep apnea | |
| US20030153515A1 (en) | Method for prevention and treatment of male and female sexual dysfunction | |
| JP5714572B2 (ja) | 精神障害およびその症状の治療のためのkcnqカリウムチャネル活性の調節方法 | |
| PINDER | 5 The Pharmacotherapy of | |
| CZ20002254A3 (cs) | Nové použití lokálních anestetik proti vaskulárním bolestem hlavy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 JUN 2015 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 JUN 2015 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: NOVARTIS AG Free format text: FORMER OWNER WAS: SPINIFEX PHARMACEUTICALS PTY LTD |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |